Introduction. Hypertension in type 2 diabetes represents a strong risk factor for cardiovascular events. Either calcium channel blockers or angiotensin receptor blockers (ARBs) may reduce insulin resistance. One of the ARBs, telmisartan (Telm) acting as a PPARγ agonist, significantly reduces HbA1C levels.The aim of this study was the comparison of the effects on glycaemic control of amlodipine (Aml) and Telm in hypertensive type 2 diabetic patients.
Materials and methods. Forty diabetic hypertensive subjects were assigned to two groups. Group A: rosiglitazone (RSG) 4 mg + Telm 80 mg; Group B: RSG 4 mg + Aml 10 mg. All the patients were already treated with metformin, but not with antihypertensive drugs.
Results. After four months treatment, both groups showed a significant reduction of mean blood pressure (Group A: - 13.5%; Group B: - 13.3%) and a positive influence on glycaemic control and insulin resistance. Lower values of glucose, HbA1C, HOMA index and higher adiponectin levels were observed in Group A compared to Group B.
Conclusions. In type 2 diabetic hypertensive patients, the association of Telm 80 mg and RSG 4 mg seems to display a metabolic advantage compared to Aml 10 mg.The simultaneous beneficial effects on blood pressure and insulin sensitivity may confer make Telm particularly suitable in the treatment of the metabolic syndrome.
Lind L., Berne C., Lithell H.Prevalence of insulin resistance in essential hypertension. J Hypertens1995;13:1457-62.
2.
Grossman E., Messerli FHDiabetic and hypertensive heart disease. Ann Intern Med1996;125:304-10.
3.
UK Prospective Diabetes Study Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetesUKPDS1998;317:703-17.
4.
Ersoy C., Imamoglu S., Budak F., Tuncel E., Eruk E., Oral B.Effect of amlodipine on insulin resistance and tumor necrosis factor-alpha in hypertensive obese type 2 diabetic patients. Indian J Med Res2004;120:481-8.
5.
Lender D., Arauz-Pacheco C., Breen L., Mora-Mora P., Ramirez LC, Raskin P.A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens1999;12:298-303.
6.
Harano Y., Kageyama A., Hirose J. et al. Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects . Metabolism1995;44:315-19.
7.
Beer NA, Jakubowicz DJ, Beer RM, Nestler JEThe calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive me. J Clin Endocrinol Metab1993;76:1464-9.
8.
Yusuf S., Gerstein H., Hoogwerf B. et al. HOPE Study Investigators. Ramipril and the development of diabetes . JAMA2001;286:1882-5.
9.
Furuhashi M. , Ura N., Higashiura K. et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension . Hypertens2003 ;42:76-81.
10.
Benson C., Pershadsing HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activit. Hypertens2004;43:993-1002.
11.
Adams M., Montague CT, Prins JB et al. Activators of peroxisome proliferator-activated receptor have depot-specific effects on human preadipocyte differentiation. J Clin Invest1997;100:3149-53.
12.
Matthews DR , Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RCHomeostasis model assessment: insulin resistance and beta-call function from fasting plasma glucose and insulin concentrations in man. Diabetologia1985;28:412-19.
13.
Miyazaki Y., Murakami H., Hirata A. et al. Effects of the angiotensin converting enzyme inhibitor temocapril on insulin sensitivity and its effects on renal sodium handling and the
14.
pressor system in essential hypertensive patients. Am J Hypertens1998;11:962-70.
15.
Iimura O., Shimamoto K., Matsuda K. et al. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens1995;8:353-7.
16.
Folli F., Saad MJ, Velloso L. et al. Crosstalk between insulin and angiotensin II signaling systems . Exp Clin Endocrinol Diabetes1999;107:133-9.
17.
Kodama J., Katayama S., Tanaka K., Itabashi A., Kawazu S., Ishii J.Effect of captopril on glucose concentration, Possible role of augmented postprandial forearm blood flow. Diabetes Care1990;13:1109-11.
18.
Higashiura K., Ura N., Takada T. et al. The effect of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens2000;13:290-7.
19.
Togashi N., Ura N., Higashiura K., Murakami H., Simamoto K.The contribution of skeletal muscle tumor necrosis factor-α to insulin resistance and hypertension in fructose-fed rats. J Hypertens2000;18:1605-10.
20.
Bogan JS, Lodis HFTwo compartments for insulinstimulated exocytosis in 3T3-L1 adipocytes defined by endogenous ACRP30 and GLUT4. J Cell Biol1999;146:609-20.
21.
Maeda N., Takahashi M., Funahashi T. et al. PPARγ ligands increase expression and plasma concentrations of adipon-ectin, an adipose-derived protein. Diabetes2001;50:2094-9.
22.
Rosen E., Sarraf P., Troy AEet al. PPARγ is required for the differentiation of adipose tissuein vivo and in vitro. Mol Cell1999;4:611-17.
23.
Tan KC, Xu A., Chow WS et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilatation. J Clin Endocrinol Metab2004 ;89:765-9.
24.
Ueshiba H., Miyachi Y., Effects of the long-acting calcium channel blockers amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern Med2004;43:561-5.
25.
Yildiz A., Hursit M., Celik AV et al. Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. Clin Nephrol2002;58:405-10.
26.
De Courten M., Ferrari P., Schneider M. et al. Lack of effect on long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. Eur J Clin Pharmacol1993;44:457-62.
27.
Baron AD, Brechtel GB, Wallace P., Edelman SVRates and tissue sites on non-insulin and insulin-mediated glucose uptake in humans, Am J Physiol1998;255:E769-E774.
28.
Draznin B., Sussman KE, Eckel RH, Kao M., Yost T., Sherman MAPossible role of cytosolic free calcium concentration in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest1988;82:1848-52.
29.
Derosa G., Ragonesi PD, Mugellini A., Ciccarelli L., Fogari R.Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double blind, placebo-controlled 12-month study. Hypertens Res2004;27:457-64.
30.
Honjo S., Nichi Y., Wada Y., Hamamoto Y., Koshiyama H.Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care2005;28:498.
